Company: PCRX
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001396814-25-000102
Chunk: 36

Company: Pacira BioSciences, Inc.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 36
---
766 shares outstanding at June 30, 2025 and 47,077,844 shares issued and 46,240,604 shares outstanding at December 31, 202448 47 Treasury stock, at cost, inclusive of excise tax and broker fees, 2,792,829 and 837,240 shares at June 30, 2025 and December 31, 2024, respectively(75,515)(25,121)     Additional paid-in capital1,035,563 1,009,435      Accumulated deficit(206,391)(206,356)     Accumulated other comprehensive income4,062 343           Total stockholders’ equity757,767 778,348           Total liabilities and stockholders’ equity$1,537,262 $1,553,516  

See accompanying notes to condensed consolidated financial statements.

Pacira BioSciences, Inc.  |  Q2 2025 Form 10-Q  |  Page 4

Table of Contents

PACIRA BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

(Unaudited)

Three Months EndedJune 30,Six Months EndedJune 30, 2025202420252024Revenues:    Net product sales$180,347 $176,387 $347,941 $342,211 Royalty revenue752 1,636 2,081 2,929           Total revenues181,099 178,023 350,022 345,140 Operating expenses:    Cost of goods sold40,866 44,262 75,172 91,678 Research and development28,200 20,338 53,893 38,576 Selling, general and administrative88,578 68,126 175,354 140,152 Amortization of acquired intangible assets14,322 14,322 28,644 28,644 Contingent consideration (gains) charges, acquisition-related expenses, restructuring and other634 2,735 6,470 4,638           Total operating expenses172,600 149,783 339,533 303,688 Income from operations8,499 28,240 10,489 41,452 Other (expense) income:    Interest